Concurrent chemoradiotherapy for advanced cervical cancer--a pilot study

J. Kodama, I. Hashimoto, N. Seki, A. Hongo, Y. Mizutani, Y. Miyagi, M. Yoshinouchi, T. Kudo

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Recently, attempts have made to use radiotherapy in combination with chemotherapy in various solid tumors including cervical cancer. Twenty-four patients with locally advanced cervical cancer were treated with concurrent Carboplatin (16-24 mg/m2/day) or Nedaplatin (20 mg/m2/week) and conventional radiotherapy. Of 13 evaluable patients, there were nine complete responders and four partial responders. There was no renal damage or grade 4 hematological toxicity. Gastrointestinal adverse reactions were mild. One patient had grade 3 dermatologic toxicity after delayed radiation therapy. This pilot study suggests that daily Carboplatin or weekly Nedaplatin administered with standard radiation therapy is safe, well-tolerated, and thus may be useful as a radiation sensitizer in the treatment of locally advanced cervical cancer.

Original languageEnglish
Pages (from-to)351-355
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume28
Issue number3
Publication statusPublished - Mar 2001

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Concurrent chemoradiotherapy for advanced cervical cancer--a pilot study'. Together they form a unique fingerprint.

Cite this